ABBV delivered what management called an "excellent start to 2026" on April 29, with immunology and neuroscience strength driving a beat that lifted shares 3.1% on the day. Yet even as the stock reclaimed $203.89 and added 1.7% for the week, something less celebratory was happening beneath the surface — short sellers were adding to positions at a pace not seen in months.
Short interest has climbed steadily and is now at its highest level in over six weeks. SI as a percentage of free float rose to 1.21% by April 29, up from around 1.05% in early April — a gain of roughly 14% in shares shorted over the month. That still sits well below any threshold that would make the short side a crowded trade. Availability in the lending market remains loose, meaning there is no shortage of supply for would-be short sellers. Cost to borrow, at 0.47% APR, has risen 37% over the past month but remains negligible in absolute terms — far too low to create any meaningful squeeze dynamic. The ORTEX short score of 31 reflects a low-conviction short setup overall: notable that shorts are building, but the borrow market is not signalling any stress.
Options positioning is broadly consistent with the modest defensive tilt. The put/call ratio is running at 1.08, fractionally above its 20-day average of 1.06 and less than half a standard deviation elevated. The 52-week range on the PCR stretches from 0.62 to 1.13, so the current reading places ABBV options well within normal territory. Taken together, the lending and options picture reads more as routine portfolio protection than as directional conviction against the stock.
The Street remains firmly constructive after Q1. Sixteen analysts carry Buy-equivalent ratings versus eight on Hold, with a consensus mean price target near $250 — implying roughly 23% upside from current levels. Recent analyst activity has been positive at the margin: Canaccord Genuity initiated with a Buy and $262 target in late April, and Guggenheim lifted its target to $249 from $242 earlier in the month. Piper Sandler trimmed fractionally — $294 to $299 — while keeping its Overweight. The bull case centres on the post-Humira pivot: immunology successor drugs, the Allergan aesthetics franchise, and the Cerevel and ImmunoGen acquisitions in neuroscience and oncology are all cited as the new growth engine. The bear case focuses on biosimilar pressure on Humira remaining a drag on the mid-term financial profile, though the Q1 print appears to have put a floor under those concerns for now. AbbVie's forward earnings yield is near 7.3%, and the PE of 13.7x is undemanding by large-cap biotech standards. The dividend score ranks in the 99th percentile of the ORTEX universe — a reminder that income investors are a structural buyer base here.
One institutional development worth flagging is the size of recent flows among the top holders. BlackRock added over 5.1 million shares in the quarter to March 31, Capital Research picked up more than 8 million shares over the same period, and Wellington added nearly 4.4 million. These are meaningful accumulations for names of that scale. Against that backdrop, the February insider sales — the CEO, CFO, and COO all sold in the $232 range on February 27 — look more like routine compensation-linked disposals at then-elevated prices than any signal of structural concern. The stock is now trading nearly 12% below those sale prices.
With the next scheduled earnings event on May 8, the setup heading into that date is: a stock that just beat, sitting on a constructive analyst tableau, with modest short rebuilding that looks more like hedging than conviction, and borrow conditions that remain easy. What to watch is whether the short interest climb continues into the May 8 event — if bears are adding in the context of a fresh beat, the catalyst they are positioning for will need to be identified from pipeline data or macro developments rather than the income statement.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
